Sethi, Ashish http://orcid.org/0000-0003-4220-3597
Horne, Christopher R. http://orcid.org/0000-0003-1318-514X
Fitzgibbon, Cheree
Wilde, Karyn http://orcid.org/0000-0002-0538-6796
Davies, Katherine A. http://orcid.org/0000-0002-4423-4664
Garnish, Sarah E.
Jacobsen, Annette V. http://orcid.org/0000-0003-0252-7685
Samson, André L. http://orcid.org/0000-0002-0637-2716
Hildebrand, Joanne M. http://orcid.org/0000-0002-1456-2042
Wardak, Ahmad http://orcid.org/0000-0003-1693-6906
Czabotar, Peter E. http://orcid.org/0000-0002-2594-496X
Petrie, Emma J.
Gooley, Paul R.
Murphy, James M. http://orcid.org/0000-0003-0195-3949
Funding for this research was provided by:
Wendy Dowsett Scholarship
Department of Health | National Health and Medical Research Council (2002965, 1142669, 1079700, 1172929, 9000653)
Department of Education and Training | Australian Research Council (LE120100022)
Article History
Received: 29 April 2021
Revised: 21 February 2022
Accepted: 21 February 2022
First Online: 9 March 2022
Competing interests
: CF, KAD, SEG, ALS, JMH, PEC, EJP, and JMM contribute to, or have contributed to, a project with Anaxis Pharma to develop necroptosis inhibitors. The remaining authors declare no competing interests.
: Mouse dermal fibroblasts were prepared using procedures approved by and conducted in accordance with the Animal Ethics Committee of the Walter and Eliza Hall Institute, Australia.